Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 6/2010

01-12-2010 | Clinical Trial Report

Is Rituximab Superior to Cyclophosphamide for ANCA-Associated Vasculitis for Induction of Remission, and with a Better Safety Profile?

Authors: Ignacio Garcia-Valladares, Luis R. Espinoza

Published in: Current Rheumatology Reports | Issue 6/2010

Login to get access

Excerpt

Jones RB, Tervaert JW, Hauser T, et al.; European Vasculitis Study Group: Rituximab versus cyclophosphamide for ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211–220. …
Literature
1.
Marquez J, Flores D, Candia L, Espinoza LR: Granulomatous vasculitis. Curr Rheumatol Rep 2003, 5:128–135.CrossRefPubMed
2.
Hoffman GS, Kerr GS, Leavitt RY, et al.: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488–498.PubMed
3.
Shovman O, Gilburd B, Zandman-Goddard G, et al.: Pathogenic role and clinical relevance of anti-neutrophil cytoplasmic antibodies in vasculitides. Curr Rheumatol Rep 2006, 8:292–298.CrossRefPubMed
4.
Chen M, Kallenberg CG: New advances in the pathogenesis of ANCA-associated vasculitides. Clin Exp Rheumatol 2009, 27:S108–S114.PubMed
5.
6.
Eriksson P, Sandell C, Backteman K, Ernerudh J: B cell abnormalities in Wegener’s granulomatosis and microscopic polyangiitis: role of CD25+ expressing B cells. J Rheumatol 2010 Aug 17 (Epub ahead of print).
7.
Keogh KA, Wylam ME, Stone JH, et al.: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:262–268.CrossRefPubMed
8.
Jones RB, Ferraro AJ, Chaudhry AN, et al.: A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60:2156–2168.CrossRefPubMed
Metadata
Title
Is Rituximab Superior to Cyclophosphamide for ANCA-Associated Vasculitis for Induction of Remission, and with a Better Safety Profile?
Authors
Ignacio Garcia-Valladares
Luis R. Espinoza
Publication date
01-12-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 6/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0133-y

Other articles of this Issue 6/2010

Current Rheumatology Reports 6/2010 Go to the issue

ReviewPaper

Giant Cell Arteritis: Epidemiology, Diagnosis, and Management

ReviewPaper

Behçet’s Syndrome

ReviewPaper

The Role of Quantitative Sensory Testing in the Evaluation of Musculoskeletal Pain Conditions

ReviewPaper

Pathophysiology of ANCA-Associated Small Vessel Vasculitis

ReviewPaper

Rheumatoid Vasculitis: Vanishing Menace or Target for New Treatments?

ReviewPaper

Is It All Central Sensitization? Role of Peripheral Tissue Nociception in Chronic Musculoskeletal Pain
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits